Wednesday, April 23, 2025 A meta-analysis completed by the EORTC using data from the following CCTG trials: BR20, BR21, BR24, BR25, BR26, BR29, CE6, CO17, CO20, C023, IND210, MA21, MA31, MY10, OV16, OV21, PA3, SC19, SC20. Lim L, Machingura A, Taye M, Pe M, Coens C, Martinelli F, Alanya A, Antunes S, Tu D, Basch E, Ringash J, Brandberg Y, Groenvold M, Eggermont A, Cardoso F, Van Meerbeeck J, Koller M, Van der Graaf WTA, Taphoorn MJB, Koekkoek JAF, Reijneveld JC, Soffietti R, Velikova G, Bottomley A, Flechtner H, Musoro J. Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study. eClinicalMedicine 82: 103153. 2025. https://www.sciencedirect.com/science/article/pii/S2589537025000859 A pooled data analysis by Quinten et al. (2009) found three European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) health-related quality of life (HRQoL) scales to be prognostic for survival: physical functioning, pain and appetite loss. This study aims to replicate these findings in an independent data set comprising a broader cancer population.
